Viridian reports Q2 2026 results as Lumvoa launch begins in the U.S.Aug 6Quarterly updateveligrotugViridian Therapeutics, Inc.\DE
FDA approves Viridian's Lumvoa for thyroid eye diseaseJun 26Regulatory decisionveligrotugViridian Therapeutics, Inc.\DE
Sign inSign in